# The Epigenome–Microbiome Axis: Host Regulation of Gut Ecology

Sushrut Ingawale

Internal Medicine Resident, Department of Internal Medicine, Frank H Netter, MD School of Medicine, Quinnipiac University; St Vincent's Medical Center, Bridgeport, Connecticut, United States

Emerging evidence reveals a dynamic epigenome–microbiome axis, whereby the host's epigenetic machinery shapes gut ecology and reciprocally the microbiota influences host gene regulation. This bidirectional interaction, particularly in the gut, holds profound implications for gastroenterology.

A seminal study demonstrated that microbial colonization alters global histone acetylation and methylation across multiple host tissues, contingent on diet. Short-chain fatty acids (SCFAs) produced through microbial fermentation were sufficient to recreate colonization-like chromatin states in germ-free mice on a polysaccharide-rich diet but not when mice were fed a Western-style diet.[1] SCFAs, especially butyrate, function as histone deacetylase inhibitors (HDACi), inducing histone hyperacetylation and transcriptional activation in intestinal epithelial cells (IECs) and systemic tissues. Aside from SCFAs, diet- and microbiome-derived metabolites—including folate, acetyl-CoA, and one-carbon cycle intermediates—contribute essential methyl and acetyl donors, influencing both deoxyribonucleic acid (DNA) methylation and histone modifications.[2]

Functionally, colonization triggers ten–eleven translocation (TET) 2/3-mediated

**Table 1:** Key studies that elucidate key host–microbiota epigenetic mechanisms

| *Study (year)* | *Model/tissue* | *Mechanism* | *Key findings* |
|---|---|---|---|
| Krautkramer et al., (2016)[1] | Mice (IECs, liver) | Microbial SCFAs → HDAC inhibition | Butyrate restored histone acetylation and transcription of colonization pathways |
| Ansari et al., (2020)[5] | Mice colon crypts | Microbiota → TET2/3-mediated DNA demethylation | Colonization induced hypomethylation of inflammation-related loci; dysbiosis worsened colitis |
| Pan et al., (2018)[6] | Postnatal IECs | Microbiota-dependent methylome establishment | Gut microbes directed methylome and transcriptome maturation during development |
| Qin et al., (2018)[7] | Human IECs | Obesity-associated dysbiosis → histone changes | Obesity-altered microbiome reshaped epigenetic landscapes in colonic IECs |

DNA demethylation in IECs, a process absent in germ-free mice. Antibiotic-induced dysbiosis suppresses TET3 expression, while intestinal insults prompt microbiota-dependent hypomethylation at key regulatory loci (e.g., *cd177*, *Pla2g2a*, *Lpo*) that modulate inflammation and barrier integrity.[3] These epigenetic programs are crucial to maintaining homeostasis and may hinder neoplastic progression. Table 1 summarizes recent studies that elucidate key host–microbiota epigenetic mechanisms.

Collectively, these findings implicate epigenetic–microbiome interplay in inflammatory bowel disease (IBD), obesity, and colorectal cancer (CRC). For example, obesity-associated dysbiosis correlates with altered epigenetic marks in colonic IECs, mediated through histone modifications. In CRC, microbial modulation of TET enzymes and histone writers/readers establishes an environment permissive to malignant transformation.

These mechanisms carry several clinical implications. First, SCFA-enriched diets or targeted probiotics—such as *Faecalibacterium prausnitzii* and *Roseburia* spp.—could beneficially reshape IEC epigenomes, improving barrier function and reducing inflammation.[4] Second, developing stool- or IEC-derived epigenetic biomarkers (e.g., histone marks, DNA methylation patterns) may enhance risk stratification for IBD or CRC. Third, combined therapeutic strategies employing epigenetic drugs (e.g., HDACi), and microbiome-targeting interventions could synergize to restore epithelial homeostasis and modulate host immunity.

Given these observations, future gastroenterology research should prioritize longitudinal, multiomic studies in at-risk or diseased cohorts, aiming to dissect causality and identify therapeutic windows. Interventional trials testing nutrient-based or microbial epigenome modulators, alone or with epigenetic drugs, are the logical next steps. Moreover, the development and validation of minimally invasive epigenetic biosensors are necessary to tailor personalized interventions.

In conclusion, the epigenome–microbiome axis represents a paradigm shift in our understanding of host–microbe crosstalk in gut health. By exploring how host epigenetic states govern microbial ecology and vice versa, we can begin to craft targeted therapies and diagnostics that modulate this relationship for better patient outcomes in a range of gastrointestinal diseases.

## Orcid

*Sushrut Ingawale* https://orcid.org/0000-0002-6938-6672

## References

1. Krautkramer KA, Kreznar JH, Romano KA, et al. Diet-microbiota interactions mediate global epigenetic programming in multiple host tissues. Mol Cell 2016;64(5):982–992.
2. Miro-Blanch J, Yanes O. Epigenetic regulation at the interplay between gut microbiota and host metabolism. Front Genet 2019;10:638.
3. Zouggar A, Haebe JR, Benoit YD. Intestinal microbiota influences DNA methylome and susceptibility to colorectal cancer. Genes (Basel) 2020;11(7):808.
4. Licciardi PV, Wong SS, Tang ML, et al. Epigenome targeting by probiotic metabolites. Gut Pathog 2010;2(1):24.
5. Ansari I, Raddatz G, Gutekunst J, et al. The microbiota programs DNA methylation to control intestinal homeostasis and inflammation. Nat Microbiol 2020;5(4):610–619.
6. Pan WH, Sommer F, Falk-Paulsen M, et al. Exposure to the gut microbiota drives distinct methylome and transcriptome changes in intestinal epithelial cells during postnatal development. Genome Med 2018;10(1):27.
7. Qin Y, Roberts JD, Grimm SA, et al. An obesity-associated gut microbiome reprograms the intestinal epigenome and leads to altered colonic gene expression. Genome Biol 2018;19(1):7.